Elena Perez Anton, Annick Dujeancourt-Henry, Brice Rotureau, Lucy Glover
{"title":"用于调查人类非洲锥虫病耐药性的下一代 CRISPR 诊断工具。","authors":"Elena Perez Anton, Annick Dujeancourt-Henry, Brice Rotureau, Lucy Glover","doi":"10.1101/2024.09.15.24313552","DOIUrl":null,"url":null,"abstract":"The WHO aims to eliminate the gambiense form of human African trypanosomiasis (HAT) by 2030. With the decrease of new reported cases, maintaining an efficient epidemiological surveillance is essential, including the emergence of drug-resistant strains. We have developed new highly specific diagnostic tools using Specific High-Sensitivity Reporter Enzymatic UnLOCKing (SHERLOCK) technology for monitoring the presence of drug-resistant genotypes that (1) are already circulating, such as the AQP2/3(814) chimera providing resistance to pentamidine and melarsoprol, or (2) could emerge, such as TbCPSF3 (N232H), associated to acoziborole resistance in lab conditions. The melarsoprol - pentamidine AQP2/3(814) SHERLOCK assay detected RNA from both cultured parasites and field isolated strains from gHAT patients in relapse following treatment. The acoziborole CPSF3(SNV) SHERLOCK assay discriminated between wild-type CPSF3 RNA and CPSF3 with a single A-C mutation that confers resistance to acoziborole in vitro.","PeriodicalId":501509,"journal":{"name":"medRxiv - Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A next generation CRISPR diagnostic tool to survey drug resistance in Human African Trypanosomiasis.\",\"authors\":\"Elena Perez Anton, Annick Dujeancourt-Henry, Brice Rotureau, Lucy Glover\",\"doi\":\"10.1101/2024.09.15.24313552\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The WHO aims to eliminate the gambiense form of human African trypanosomiasis (HAT) by 2030. With the decrease of new reported cases, maintaining an efficient epidemiological surveillance is essential, including the emergence of drug-resistant strains. We have developed new highly specific diagnostic tools using Specific High-Sensitivity Reporter Enzymatic UnLOCKing (SHERLOCK) technology for monitoring the presence of drug-resistant genotypes that (1) are already circulating, such as the AQP2/3(814) chimera providing resistance to pentamidine and melarsoprol, or (2) could emerge, such as TbCPSF3 (N232H), associated to acoziborole resistance in lab conditions. The melarsoprol - pentamidine AQP2/3(814) SHERLOCK assay detected RNA from both cultured parasites and field isolated strains from gHAT patients in relapse following treatment. The acoziborole CPSF3(SNV) SHERLOCK assay discriminated between wild-type CPSF3 RNA and CPSF3 with a single A-C mutation that confers resistance to acoziborole in vitro.\",\"PeriodicalId\":501509,\"journal\":{\"name\":\"medRxiv - Infectious Diseases\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv - Infectious Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2024.09.15.24313552\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Infectious Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.09.15.24313552","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A next generation CRISPR diagnostic tool to survey drug resistance in Human African Trypanosomiasis.
The WHO aims to eliminate the gambiense form of human African trypanosomiasis (HAT) by 2030. With the decrease of new reported cases, maintaining an efficient epidemiological surveillance is essential, including the emergence of drug-resistant strains. We have developed new highly specific diagnostic tools using Specific High-Sensitivity Reporter Enzymatic UnLOCKing (SHERLOCK) technology for monitoring the presence of drug-resistant genotypes that (1) are already circulating, such as the AQP2/3(814) chimera providing resistance to pentamidine and melarsoprol, or (2) could emerge, such as TbCPSF3 (N232H), associated to acoziborole resistance in lab conditions. The melarsoprol - pentamidine AQP2/3(814) SHERLOCK assay detected RNA from both cultured parasites and field isolated strains from gHAT patients in relapse following treatment. The acoziborole CPSF3(SNV) SHERLOCK assay discriminated between wild-type CPSF3 RNA and CPSF3 with a single A-C mutation that confers resistance to acoziborole in vitro.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
